StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Inhibikase Therapeutics's profit margin for the twelve months ending Sep 30, 2024 was -1956524900.0%. For fiscal 2023 it was -7304.7%, against -14625.9% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-7304.7%+7321.1
FY2022Dec 31, 2022-14625.9%−14149.0
FY2021Dec 31, 2021-476.9%−69.1
FY2020Dec 31, 2020-407.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 2023-417794000.0%−417787268.3
Q3 FY2023Sep 30, 2023-5775.1%+55870.2
Q2 FY2023Jun 30, 2023-4963.5%+65853.7
Q1 FY2023Mar 31, 2023-6940.0%+3141.4
Q4 FY2022Dec 31, 2022-6731.7%−6538.3
Q3 FY2022Sep 30, 2022-61645.4%−61458.0
Q2 FY2022Jun 30, 2022-70817.1%−70108.3
Q1 FY2022Mar 31, 2022-10081.5%−8301.7
Q2 FY2021Jun 30, 2021-193.4%−1.3
Q1 FY2021Mar 31, 2021-187.4%+14.8
Q4 FY2020Dec 31, 2020-708.8%–
Q3 FY2020Sep 30, 2020-1779.7%–
Q2 FY2020Jun 30, 2020-192.1%–
Q1 FY2020Mar 31, 2020-202.2%–

More Inhibikase Therapeutics figures

See a number that looks wrong?